|
|
Vaccine Detail
|
ALVAC-B7-CEA |
| Vaccine Information |
- Vaccine Name: ALVAC-B7-CEA
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007241
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CD80
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- CEACAM5 (CEA)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: ALVAC-CEA/B7.1 was prepared by recombinant engineering. On the day of vaccination, the vaccine was reconstituted with 1 mL of 0.4% NaCl diluent and shaken gently. A sterile syringe was used to inject 1 mL of solution s.c. in the deltoid region (Kaufman et al., 2008).
- Description: A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-B7-CEA expresses carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cells, and B7.1 (also known as CD80), the natural ligand for the T-cell antigen CD28, to augment the host immune response. This agent has been shown to stimulate a host immune response against tumor cells that express CEA. This vaccine has been used in melanoma patients. (van et al., 2005; NCIT_C2742).
|
| Host Response |
|
|
| References |
Kaufman et al., 2008: Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(15); 4843-4849. [PubMed: 18676757].
NCIT_C2742: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2742]
van et al., 2005: van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(35); 9008-9021. [PubMed: 16061912].
|
|
